|
I have published NeuroInvestment since mid-1995. I have a clinical background,(Ph.D), with a private practice in clinical/neuropsychology. I recommended CNSI in March 1996, and it continues to be on the Recommended List. The 1997 target is 15, largely because I do not expect definitive Phase III data to be available until 1Q:1998. At that point the price should easily move above 20. Depending on the mood of the market overall, and the magnitude of Cerestat's effect in the trials, Boni's 12 month target of 35 may be attainable. If stunning results in both stroke and head trauma were found, his upper price estimate might be reachable, but only if the overall market had turned back to small-cap biotechs. I generally have 6-8 companies recommended at any given time, and currently I have positions in about half of them. Currently I do not have a position in CNSI, but that has nothing to do with my view of the Company, and that could change. The key to Cerestat is the fact that many of its competitors have flagged and failed, it and citicoline (IPIC) could be the next major (and complementary, not competing) stroke drugs to come to market. NeuroInvestment |
